Orally bioavailable glutamine antagonist prodrug JHU-083 penetrates mouse brain and suppresses the growth of MYC-driven medulloblastomaAllison R. Hanaford, Eric H. Raabe, Jesse Alt et al.|Translational Oncology|2019Cited by 74
Unbiased Metabolic Profiling Predicts Sensitivity of High MYC-Expressing Atypical Teratoid/Rhabdoid Tumors to Glutamine Inhibition with 6-Diazo-5-Oxo-L-NorleucineSabrina Wang, Jeffrey Rubens, Brad Poore et al.|Clinical Cancer Research|2019Cited by 34
Inhibition of mTORC1 in pediatric low-grade glioma depletes glutathione and therapeutically synergizes with carboplatinBrad Poore, Eric H. Raabe, Ming Yuan et al.|Neuro-Oncology|2018Cited by 28
Novel Glutamine Antagonist JHU395 Suppresses MYC-Driven Medulloblastoma Growth and Induces ApoptosisKhoa Pham, Eric H. Raabe, Micah J. Maxwell et al.|Journal of Neuropathology & Experimental Neurology|2021Cited by 27
Comprehensive Metabolic Profiling of MYC-Amplified Medulloblastoma Tumors Reveals Key Dependencies on Amino Acid, Tricarboxylic Acid and Hexosamine PathwaysKhoa Pham, Eric H. Raabe, Charles G. Eberhart et al.|Cancers|2022Cited by 21